Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) EBIT (2017 - 2019)

Historic EBIT for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to -$1.2 million.

  • Monopar Therapeutics' EBIT fell 3222.7% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 3688.5%. This contributed to the annual value of -$4.3 million for FY2019, which is 2979.8% down from last year.
  • Latest data reveals that Monopar Therapeutics reported EBIT of -$1.2 million as of Q4 2019, which was down 3222.7% from -$759448.0 recorded in Q3 2019.
  • Over the past 5 years, Monopar Therapeutics' EBIT peaked at -$373839.0 during Q1 2017, and registered a low of -$14.9 million during Q3 2017.
  • In the last 3 years, Monopar Therapeutics' EBIT had a median value of -$828354.0 in 2018 and averaged -$2.0 million.
  • Data for Monopar Therapeutics' EBIT shows a peak YoY increase of 9551.92% (in 2018) and a maximum YoY decrease of 14001.24% (in 2018) over the last 5 years.
  • Quarter analysis of 3 years shows Monopar Therapeutics' EBIT stood at -$736800.0 in 2017, then fell by 25.73% to -$926358.0 in 2018, then tumbled by 32.23% to -$1.2 million in 2019.
  • Its last three reported values are -$1.2 million in Q4 2019, -$759448.0 for Q3 2019, and -$932109.0 during Q2 2019.